Ropes & Gray advised Erasca, Inc. on the deal. Erasca, Inc. (Nasdaq: ERAS), a precision oncology company, announced it has entered into an exclusive license agreement...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP advised Erasca on the offering. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Erasca on the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
